Background

What do we already know about this topic?

• Current treatment of metastatic melanoma is based on immune checkpoint inhibition and targeted therapy, and there are excellent long-term survival rates with current options.
• However, a substantial number of patients are primary resistant or become resistant, and there is a burden of adverse events.